Navigation Links
Greater Efficacy on Cognition and Function Over Current Treatments Remain Neurologists' Top Unmet Need in Mild to Moderate Alzheimer's Disease
Date:9/23/2013

BURLINGTON, Mass., Sept. 23, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that drugs offering a greater effect on cognition and those offering a greater effect on function compared with current treatments remain the top unmet needs in the treatment of mild to moderate Alzheimer's disease (AD), according to surveyed U.S. and European neurologists. Currently available therapies alleviate some cognitive and functional symptoms associated with AD over the short-term, but do not slow disease progression, thus underscoring the remaining unmet need for more efficacious alternatives, which could be either symptomatic or disease-modifying.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The DecisionBase report entitled Alzheimer's Disease (Mild to Moderate): In an Increasingly Generic Market, What Attributes Can Differentiate Novel Brands in the Minds of Physicians and Payers? also finds that, based on a product profile presented, surveyed U.S. neurologists would prescribe Eli Lilly's emerging anti-beta-amyloid monoclonal antibody solanezumab to a median 15 percent of their mild to moderate AD patients. Interviewed thought leaders are encouraged by a slowing of cognitive decline observed in solanezumab-treated mild AD patients, pooled across two completed, placebo-controlled, Phase III studies, as well as the drug's safety profile, particularly with regard to a low risk of amyloid-related imaging abnormalities.

The report also includes insights from a survey of U.S. managed care organization pharmacy directors, two-thirds of whom indicate they would reimburse a new disease-modifying therapy for the treatment of mild to moderate AD that was priced at a significant premium to current brands ($25/day), if such an agent offered a 200 percent improvement on cognitive decline over donepezil (Eisai/Pfizer's Aricept, other brands, generics). Payers expecting not to cover such a therapy mostly cite insufficient benefits as the reason, suggesting that—for some payers—greater therapeutic gains would be needed to justify the value of a drug offered at such a considerable cost.

"With a new Phase III trial ongoing in mild AD, solanezumab retains the potential to become the first disease-modifying therapy approved for the treatment of this debilitating disease, a landmark achievement," said Decision Resources Senior Business Insights Analyst Alana Simorellis, Ph.D. "We expect solanezumab likely would be priced much higher than symptomatic brands today, which could present challenges to usage and market access, depending on the level of its clinical benefits. Even with limited uptake, however, we expect premium pricing and a growing patient population could easily drive blockbuster sales for solanezumab in the AD market over the next decade."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Diagnostic Imaging Releases Recommendations For Greater Reading Room Comfort
2. End Users Desire for Greater Control over Production Processes Increases Adoption of SISs in Europe, Finds Frost & Sullivan
3. NxStage Urges CMS to Fix Training Reimbursement to Provide Medicare Patients Greater Access to Life-Changing Home Hemodialysis Therapies
4. Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022
5. CPhI Report Indicates a Need for Greater Third Party Certification to Ensure GMP Vigilance
6. Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services
7. A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
8. Smart911 and In Case of Emergency Standard Partner to Enhance Availability of Life Saving Data for Greater Emergency Response
9. Cancer drug shortages mean higher costs and greater risk for patients
10. New Report Details NCPA Efforts to Drive Greater Medication Adherence
11. Greater New York Dental Meeting and Inside Dental Technology Announce Collaboration 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... Jan. 19, 2017 Report Details ... Which areas are going to grow at the fastest ... 2026, assessing data, trends, opportunities and prospects. Our ... the most lucrative areas in the industry and the ... forecasted sales across the all the major categories of ...
(Date:1/19/2017)... , Jan. 19, 2017 Conference Call and Webcast to ... ) today announced it will release results for the fourth quarter ... ... host a conference call at 4:30 PM ET on Wednesday, February ... full year 2016 financial results and other corporate activities. To participate ...
(Date:1/19/2017)... Jan. 19, 2017 Many patients don,t realize ... medication when a pharmacy just a few blocks away ... alleviate this problem Medicationdiscountcard.com has created a ... exactly how much their medication will cost at most ... Medicationdiscountcard.com takes all ...
Breaking Medicine Technology:
(Date:1/20/2017)... raton florida (PRWEB) , ... January 20, 2017 , ... ... at the Dana Farber Cancer Institute. For Betsy, the clinical trial has been ... her cancer has not worsened. , Betsy Brauser was diagnosed with ovarian cancer ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Code Word: Chocolate Biscuit”: a biographical account following a man ... is the creation of published author, Marlyn Ivey, born in Lynn Haven, Florida and at ... school and at 19 years of age, he joined the Navy and got married right ...
(Date:1/20/2017)... , ... January 20, 2017 , ... “Knowledge is God’s ... guided by faith. “Knowledge is God’s Lighthouse” is the creation of published author, Gene ... novels, and poetry collections. , “I have been writing since high school and ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Next week after ... be repealed by Congressional political games that circumvent health needs of over 30 million. ... capture the human anxieties and needs government public servants were suppose to prioritize. Interviews ...
(Date:1/19/2017)... ... January 19, 2017 , ... WhoHaha , a digital media company ... Heart Association (AHA) to produce a three-part video series that uses humor to highlight ... of the launch of AHA’s Healthy For Good™ movement, which is designed to inspire ...
Breaking Medicine News(10 mins):